Exhibit 10.1


 


Execution Version


 


EXCHANGE AGREEMENT


 


This Exchange Agreement (this “Agreement”)
is made and entered into as of July 28, 2021, by and among John C. Malone (“Dr. Malone”), the John C. Malone 1995
Revocable Trust U/A DTD 3/6/1995 (the “Trust”) and Liberty Media Corporation, a Delaware corporation (the “Company”).


 


RECITALS


 


WHEREAS, as of June 30, 2021, Dr. Malone beneficially
owns shares of Common Stock constituting approximately 48.6% of the outstanding voting power of the Company and approximately 47.5%, 47.6%
and 49.0% of the outstanding voting power of the Braves Group, the Formula One Group and the Sirius XM Group, respectively; and


 


WHEREAS, the Company and Dr. Malone have agreed
to enter into the arrangements contemplated by this Agreement in light of, among other things, the fact that the Malone Voting Power in
reference to each Group and the Company could become a majority.


 


NOW, THEREFORE, in consideration of the covenants
and agreements contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged,
the parties hereby agree as follows:


 


1.             Definitions.


 


“Accretive Event Notice” has
the meaning set forth in Section 3(a).


 


“Accretive Event” means, with
respect to the Voting Securities of a Group, any event resulting in (i) the decrease of the Outstanding Votes of such Group, whether by
repurchase, redemption, conversion of the Voting Securities of such Group (including any conversion of shares of Series B Common Stock
of such Group into shares of Series A Common Stock of such Group) or otherwise or (ii) Dr. Malone’s beneficial ownership of Voting
Securities of such Group increasing (excluding through a Voting Power Exchange), in either case, without duplication and immediately following
which, and after taking into account any concurrent or substantially concurrent other event resulting in (a) the effects described in
clauses (i) or (ii) above, (b) the effects described in clause (i) or (ii) of the definition of Dilutive Event or (c) a Fundamental Event,
the Malone Voting Power with respect to such Group would be greater than 0.5% plus the Target Voting Power.


 


“Action” means any claim, audit,
action, suit, proceeding, arbitration, mediation or investigation by or before any Governmental Authority.


 


“Affiliate” means, with respect
to any Person, any other Person that directly, or indirectly through one or more intermediaries, controls, is controlled by, or is under
common control with such specified Person, for so long as such Person remains so affiliated to the specified Person. For purposes of this
definition, and for the avoidance of doubt, natural persons shall not be deemed to be Affiliates of each other.


 






    


     


    

 


“Agreement” has the meaning
set forth in the preamble.


 


“Available Series B Shares”
means, with respect to a Group, at the time of any determination thereof, a number of shares of Series B Common Stock of such Group equal
to (x) the aggregate number of Reverse Exchange Shares of such Group delivered to the Company at any one or more Reverse Exchange Closings
occurring prior to such time of determination, minus (y) the aggregate number of shares of Series B Common Stock of such Group
delivered to Dr. Malone or the Trust at any one or more prior Dilutive Event Exchange Closings, Fundamental Event Exchange Closings, or
Voting Power Exchange Closings occurring prior to such time of determination. For the avoidance of doubt, there are no Available Series
B Shares of any Group as of the date of this Agreement.


 


“beneficial owner”, “beneficial
ownership” and “beneficially owns” have the meanings given to such terms in Rule 13d-3 under the Exchange
Act, and beneficial ownership of capital stock or any other equity security which is then entitled to vote generally in the election of
directors shall be calculated in accordance with the provisions of such Rule; provided, however, that, for purposes of determining beneficial
ownership, (a) in respect of Dr. Malone or any Proposed Transferee, such Person shall be deemed to be the beneficial owner of any Equity
which may be acquired by such Person (disregarding any conditions or legal impediments to such beneficial ownership), whether within sixty
(60) days or thereafter, upon the conversion, exchange or exercise of any warrants, options, rights or other securities, (b) notwithstanding
clause (a), none of Dr. Malone or any Proposed Transferee shall be deemed to beneficially own any Available Series B Shares unless and
until Dr. Malone or such Proposed Transferee, as applicable, acquires such shares at an Exchange Closing pursuant to the terms of this
Agreement, and Dr. Malone will cease to beneficially own any shares of Series B Common Stock upon delivery of such shares to the Company
at any Reverse Exchange Closing, (c) notwithstanding clause (a), Dr. Malone shall not be deemed to beneficially own any shares of Series
A Common Stock into which any shares of Series B Common Stock beneficially owned by Dr. Malone may be converted pursuant to the Company
Charter, (d) Dr. Malone shall not be deemed to beneficially own any Equity solely as a result of Dr. Malone’s execution of this
Agreement or Dr. Malone’s filing of any reports, forms or schedules with the SEC or other Governmental Authority in connection with
any of the matters contemplated hereby, (e) Dr. Malone and any Proposed Transferee shall be deemed, respectively, to beneficially own
any Voting Securities beneficially owned by any respective Controlled Affiliate of such Person, and (f) notwithstanding clause (b) above,
a Proposed Transferee shall be deemed to beneficially own, any Available Series B Shares that would be the subject of any Successor Exchange
Agreement.


 


“Board” means the board of directors
of the Company.


 


“Braves Group” shall have the
meaning ascribed thereto in the Company Charter as of the date of determination.


 


“Business Day” means any day
that is not a Saturday, a Sunday or other day on which banks are required or authorized by Law to be closed in the City of New York.


 


“Code” means the Internal Revenue
Code of 1986, as amended.


 






    2


     


    

 


“Common Stock” means any or
all Common Stock of the Company designated as such in the Company Charter.


 


“Company” has the meaning set
forth in the preamble.


 


“Company Bylaws” means the Bylaws
of the Company, as amended from time to time.


 


“Company Charter” means the
Restated Certificate of Incorporation of the Company, as amended from time to time.


 


“Company Exchange Shares” means
(i) any shares of Series C Common Stock issued and/or delivered in a Reverse Exchange and (ii) any Available Series B Shares issued and/or
delivered in a Dilutive Event Exchange, Fundamental Event Exchange or Voting Power Exchange.


 


“Company Rescission Shares”
shall have the meaning set forth in Section 6(b).


 


“Competition Law” means any
Law that is designed or intended to prohibit, restrict or regulate actions having the purpose or effect of monopolization or lessening
of competition through merger or acquisition or restraint of trade.


 


“Controlled Affiliate” means
with respect to any Person, any other Person (other than an individual) controlled by such Person. For the purpose of this definition,
the term “control” (including, with a correlative meaning, the term “controlled by”), as used with respect to
any Person, means (i) beneficial ownership, directly or indirectly, of securities of any Person that represent more than 50% of the vote
in the election of directors (or equivalent), (ii) otherwise being entitled to nominate or designate, directly or indirectly, a majority
of the directors (or equivalent) or (iii) in the case of a limited partnership or limited liability company, being a general partner or
managing member and having the power to direct the policies, management and affairs of such entity.


 


“Delaware Courts” has the meaning
set forth in Section 15.


 


“Dilutive Event” means, with
respect to the Voting Securities of a Group, any event resulting in (i) the increase of the Outstanding Votes of such Group, whether upon
the exercise of stock options, conversion of any convertible security, issuance of capital stock or otherwise, or (ii) Dr. Malone’s
beneficial ownership of Voting Securities of such Group decreasing, immediately following which, and after taking into account any concurrent
or substantially concurrent other event resulting in (a) the effects described in clauses (i) or (ii) above, (b) the effects described
in clauses (i) or (ii) of the definition of Accretive Event, or (c) a Fundamental Event, the Malone Voting Power in respect of such Group
would be less than the Target Voting Power minus 0.5%.


 


“Dilutive Event Exchange” has
the meaning set forth in Section 2(d)(iii).


 


“Dilutive Event Exchange Closing”
has the meaning set forth in Section 2(b).


 


“Dilutive Event Notice” has
the meaning set forth in Section 2(a).


 






    3


     


    

 


“Dr. Malone” has the meaning
set forth in the preamble.


 


“Encumbrance” means any mortgage,
deed of trust, lien (statutory or otherwise), pledge, hypothecation, charge, title retention device, restriction, covenant, title defect,
assignment, adverse claim, encumbrance, option, right of first refusal or first offer, preemptive right or security interest of any kind
or nature (including any restriction on the voting of any security, any restriction on the transfer of any security or other asset, any
restriction on the receipt of any income derived from any asset, any restriction on the use of any asset and any restriction on the possession,
exercise or transfer of any other attribute of ownership of any asset).


 


“Equity” means any and all shares
of capital stock and securities issuable upon the conversion, exercise or exchange of securities.


 


“Exchange” means a Dilutive
Event Exchange, a Reverse Exchange, a Voting Power Exchange, or a Fundamental Event Exchange.


 


“Exchange Act” means the Securities
Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.


 


“Exchange Closing” means a Dilutive
Event Exchange Closing, a Reverse Exchange Closing, a Fundamental Event Exchange Closing or a Voting Power Exchange Closing.


 


“Exchange Event” means a Dilutive
Event, an Accretive Event or a Fundamental Event.


 


“Family Member” means a descendant
of a parent of either John C. Malone or Leslie A. Malone, or any trust whose sole beneficiaries are one or more descendants of a parent
of either John C. Malone or Leslie A. Malone and, in the case of a charitable remainder trust, a charitable beneficiary.


 


“Formula One Group” shall have
the meaning ascribed thereto in the Company Charter as of the date of determination.


 


“Fundamental Event” means any
combination, consolidation, merger, exchange offer, split-off, spin-off, rights offering or dividend, in each case, as a result of which
holders of Series B Common Stock of one or more Groups are entitled to receive securities of the Company, securities of another Person,
property or cash, or a combination thereof.


 


“Fundamental Event Exchange”
has the meaning set forth in Section 4(a)(ii).


 


“Fundamental Event Exchange Closing”
has the meaning set forth in Section 4(a)(ii).


 


“Governmental Authority” means
any supranational, national, federal, state, county, local or municipal government, or other political subdivision thereof, or any court,
tribunal or arbitral body and any entity exercising executive, legislative, judicial, regulatory, taxing, administrative, prosecutorial
or arbitral functions of or pertaining to government, domestic or foreign; provided, that such term shall not include any stock
exchange or listing company.


 






    4


     


    

 


“Group” means, as applicable,
the Sirius XM Group, the Braves Group or the Formula One Group, or any other tracking stock group that may be created from time to time
after the date hereof which is intended to track the performance of a specified group of assets and businesses of the Company. For the
avoidance of doubt, in the event the Company Charter is amended to eliminate the tracking stock capitalization structure of the Company,
the term “Group” shall refer to the Company.


 


“HSR Act” means the Hart-Scott-Rodino
Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder.


 


“Independent Director” means
a member of the Board who (i) qualifies as an “Independent Director” as defined in the NASDAQ
Marketplace Rules or who qualifies as “independent” under the applicable rules and regulations of any other national
securities exchange on which the Common Stock is publicly traded on or after the date hereof and
(ii) is independent for purposes of Delaware law (as determined in good faith by the Board) from Dr. Malone and, in connection with approval
of a Successor Exchange Agreement, from any counterparties thereto.


 


“Law” means all foreign, federal,
state, provincial, local or municipal laws (including common law), statutes, ordinances, regulations and rules of any Governmental Authority,
and all Orders.


 


“Malone Rescission Shares” shall
have the meaning set forth in Section 6(b).


 


“Malone Series C Exchangeable Shares”
means, with respect to any Group, and at the time of any determination thereof, a number of shares of Series C Common Stock of such Group
equal to the number of Available Series B Shares of such Group at such time.


 


“Malone Voting Power” means,
at the time of any determination thereof, (i) when used in reference to a particular Group, the aggregate voting power of the Voting Securities
of such Group with respect to which Dr. Malone has beneficial ownership as a percentage of the voting power of all outstanding Voting
Securities of such Group and (ii) when used in reference to the Company, the aggregate voting power of the Voting Securities of the Company
with respect to which Dr. Malone has beneficial ownership as a percentage of the voting power of all outstanding Voting Securities of
the Company.


 


“Maximum Amount” has the meaning
set forth in Section 5(a).


 


“Order” means any judgment,
order, writ, award, preliminary or permanent injunction or decree of any Governmental Authority.


 


“Other Voting Securities” has
the meaning set forth in Section 5(a).


 


“Outstanding Votes” means, at
the time of any determination thereof, and in respect of any Group, the total number of votes that may be cast by the holders of the outstanding
Voting Securities of such Group in their capacity as such at any meeting of stockholders of the Company at which matters generally voted
on by the holders of Voting Securities are to be considered.


 






    5


     


    

 


“Permitted Encumbrance” means
(i) any Encumbrance under this Agreement (including, without limitation, pursuant to Section 6 hereof), and (ii) any restrictions
on Transfer arising under securities Laws of general applicability.


 


“Person” means any individual,
corporation, limited liability company, limited or general partnership, joint venture, association, joint-stock company, trust, unincorporated
organization, Governmental Authority or any group comprised of two (2) or more of the foregoing.


 


“Proposed Transferee” means
any Family Member or group of Family Members (as group is used in Section 13(d) under the Exchange Act) to whom Dr. Malone (or his executors,
administrators or testamentary trustees) or the Trust proposes to Transfer (or does Transfer) Voting Securities.


 


“Rescission” has the meaning
set forth in Section 6(a).


 


“Rescission Exchange” has the
meaning set forth in Section 9.


 


“Reverse Exchange” has the meaning
set forth in Section 3(c)(iii).


 


“Reverse Exchange Closing” has
the meaning set forth in Section 3(b).


 


“Reverse Exchange Shares” has
the meaning set forth in Section 3(c)(i).


 


“SEC” means the United States
Securities and Exchange Commission.


 


“Securities Act” means the Securities
Act of 1933, as amended, and the rules and regulations promulgated thereunder.


 


“Series A Common Stock” means
(i) the series of Common Stock designated as “Series A Liberty Sirius XM Common Stock” in the Company Charter, (ii) the series
of Common Stock designated as “Series A Liberty Braves Common Stock” in the Company Charter, (iii) the series of Common Stock
designated as “Series A Liberty Formula One Common Stock” in the Company Charter and (iv) any other series of voting Common
Stock created after the date hereof in respect of a newly created Group the holders of which are generally entitled to the lowest positive
number of votes per share for series of Common Stock with respect to such Group in matters submitted to the stockholders of the Company
for a vote.


 


“Series B Common Stock” means
(i) the series of Common Stock designated as “Series B Liberty Sirius XM Common Stock” in the Company Charter, (ii) the series
of Common Stock designated as “Series B Liberty Braves Common Stock” in the Company Charter, (iii) the series of Common Stock
designated as “Series B Liberty Formula One Common Stock” in the Company Charter and (iv) any other series of voting Common
Stock created after the date hereof in respect of a newly created Group the holders of which are generally entitled to the highest number
of votes per share for series of Common Stock with respect to such Group in matters submitted to the stockholders of the Company for a
vote.


 






    6


     


    

 


“Series C Common Stock” means
(i) the series of Common Stock designated as “Series C Liberty Sirius XM Common Stock” in the Company Charter, (ii) the series
of Common Stock designated as “Series C Liberty Braves Common Stock” in the Company Charter, (iii) the series of Common Stock
designated as “Series C Liberty Formula One Common Stock” in the Company Charter and (iv) any other series of nonvoting Common
Stock created after the date hereof in respect of a newly created Group.


 


“Sirius XM Group” shall have
the meaning ascribed thereto in the Company Charter as of the date of determination.


 


“Special Committee” means any
committee of the Board consisting solely of Independent Directors.


 


“Successor Exchange Agreement”
means an exchange agreement between the Company and one or more Proposed Transferees, in substantially the form of this Agreement (as
determined in good faith by a Special Committee or a majority of the Independent Directors) with such modifications as are reasonably
necessary such that if, as of the time of execution of such exchange agreement, such Proposed Transferee’s beneficial ownership
of any Group as a percentage of the voting power of all outstanding Voting Securities of such Group is (or would be, after taking into
account the proposed Transfer) greater than the Target Voting Power, such Person agrees to transfer shares of Series B Common Stock of
such Group to the Company in exchange for shares of Series C Common Stock of such Group on a one to one basis so that such Person’s
beneficial ownership of shares of such Group as a percentage of the voting power of all outstanding Voting Securities of such Group does
not exceed by more than 0.5% the Target Voting Power of such Group; provided that such transfer requirement may be satisfied, with
respect to any Available Series B Shares subject of such Successor Exchange Agreement, by execution of such Successor Exchange Agreement.


 


“Surviving Company” means the
entity whose securities are received by Dr. Malone or the Trust in a Fundamental Event.


 


“Target Voting Power” means
49.0%.


 


“Tax” or “Taxes”
means (a) any and all federal, state, local and foreign taxes and other assessments, governmental charges, duties, fees, levies and liabilities
in the nature of a tax, including gross receipts, income, profits, sales, use, occupation, value added, ad valorem, transfer, franchise,
withholding, payroll, recapture, escheat, employment, excise and property taxes and (b) all interest, penalties and additions imposed
with respect to such amounts in clause (a).


 


“Tax Return” means a report,
return, certificate, form or similar statement or document, including any amendment thereof or any attachment thereto, supplied to or
filed with or required to be supplied to or filed with a Governmental Authority in connection with the determination, assessment or collection
of any Tax, including an information return, claim for refund, amended return or declaration of estimated Tax.


 


“Transfer” means a sale, transfer
or disposition of beneficial ownership, directly or indirectly, whether by operation of law or otherwise; provided, however, the
granting of any proxy or the agreement to vote any Voting Securities, in each case in connection with a Fundamental Event, will not be
deemed a Transfer of beneficial ownership of the underlying shares.


 






    7


     


    

 


“Trust” has the meaning set
forth in the preamble.


 


“Voting Power Demand” has the
meaning set forth in Section 5(a).


 


“Voting Power Exchange” has
the meaning set forth in Section 5(c)(iii).


 


“Voting Power Exchange Closing”
has the meaning set forth in Section 5(b).


 


“Voting Securities” shall (i)
with respect to the Company, have the meaning set forth in the Company Charter, together with any shares of a new class or series of capital
stock of the Company issued after the date hereof which by the terms of any amendment to the Company Charter (including through the effectiveness
of a Preferred Stock Designation (as defined in the Company Charter)) is designated as a Voting Security and (ii) with respect to a Surviving
Company, mean stock of any class or series entitled to vote generally in the election of directors (or, with respect to any entity that
is not a corporation, any equity interest entitled to vote generally in the election of the governing body of such entity).


 


2.             Exchange Upon Dilutive Events.


 


		(a)	If the Company proposes to consummate any Dilutive Event with respect to a Group or receives notice of any occurrence, event or fact
that would reasonably be expected to cause, or has caused, a Dilutive Event with respect to a Group and, in each case, the number of Available
Series B Shares of such Group at the time of such Dilutive Event is a positive number, the Company shall provide prompt written notice
to Dr. Malone (a “Dilutive Event Notice”), specifying the number and series of the shares of Voting Securities involved
in such Dilutive Event, the nature and timing of the Dilutive Event, the Group with respect to which the Dilutive Event has occurred or
will occur, a reasonable estimate of the Malone Voting Power in such Group after giving effect to such Dilutive Event (for the avoidance
of doubt, without giving effect to any Dilutive Event Exchange in respect thereof) and a reasonable estimate of the number of shares of
Series C Common Stock of such Group to be exchanged by Dr. Malone and the Trust collectively in connection with such Dilutive Event.
	 	 	 
	 	(b)	Subject to the last sentence of Section 2(c),
the consummation and closing of any Dilutive Event Exchange will take place as promptly as practicable following the latest to occur of
(x) the receipt of a Dilutive Event Notice by Dr. Malone, (y) the occurrence of the Dilutive Event, and (z) the receipt of any necessary
regulatory approvals required for Dr. Malone and the Company to complete such Dilutive Event Exchange (including pursuant to the HSR Act
or any other Competition Law) (the “Dilutive Event Exchange Closing”), and at a location and time agreed to by Dr.
Malone and the Company; provided, however, that the conditions set forth in Sections 10, 11 and 12 shall have been
satisfied (or waived by the party entitled to the benefit thereof).




 






    8


     


    

 


		(c)	The number of shares of Series C Common Stock of a Group which shall be exchanged by Dr. Malone and/or the Trust in the Dilutive Event
Exchange shall be an amount equal to the lesser of (x) the number of shares of Series B Common Stock of the same Group, the beneficial
ownership of which by Dr. Malone or the Trust would cause the Malone Voting Power of such Group immediately following the consummation
and closing of such Dilutive Event Exchange to be as close as possible to being equal to, but without being greater than, the Target Voting
Power, and (y) the number of Available Series B Shares of such Group at such time. The Company shall determine such number of shares to
be exchanged and provide Dr. Malone with notice of the same at least five Business Days prior to the Dilutive Event Exchange Closing (which
notice may be included in a Dilutive Event Notice); provided, however, that Dr. Malone may elect to exchange fewer (or no) shares
of such Series C Common Stock upon written notice to the Company.
	 	 	 
	 	(d)	At any Dilutive Event Exchange Closing, on the terms
and subject to the conditions contained in this Agreement (including after giving effect to any adjustments in accordance with Section
19(d) hereof):




 


		(i)	Dr. Malone and the Trust, as applicable, shall convey, transfer and deliver to the Company their respective number of shares of Series
C Common Stock of the applicable Group determined in accordance with Section 2(c), free and clear of all Encumbrances other than
Permitted Encumbrances;



 


		(ii)	the Company shall issue and/or deliver to Dr. Malone and the Trust, as applicable, such number of shares of Series B Common Stock
of the same Group as is equal to such number of shares of Series C Common Stock of such Group delivered by Dr. Malone and the Trust, respectively,
and such shares of Series B Common Stock shall be duly authorized, validly issued, fully paid and nonassessable and free and clear of
all Encumbrances other than Permitted Encumbrances; and



 


		(iii)	the Company and Dr. Malone and the Trust, as applicable, will duly execute and deliver a cross receipt each acknowledging the receipt
of the shares of Common Stock delivered to it in connection therewith (the transactions described in this clause (d) being a “Dilutive
Event Exchange”).



 


3.             Reverse Exchange Upon Accretive Events.


 


	 	(a)	If the Company proposes to consummate any Accretive Event with respect to a Group or receives notice of any occurrence, event or fact that would reasonably be expected to cause, or has caused, an Accretive Event with respect to a Group, the Company shall provide prompt written notice to Dr. Malone (an “Accretive Event Notice”), specifying the number and series of the shares of Voting Securities involved in such Accretive Event, the nature and timing of the Accretive Event, the Group with respect to which the Accretive Event has occurred or will occur, a reasonable estimate of the Malone Voting Power in such Group after giving effect to such Accretive Event (for the avoidance of doubt, without giving effect to any Reverse Exchange in respect thereof) and a reasonable estimate of the number of Reverse Exchange Shares of such Group to be exchanged by Dr. Malone and the Trust collectively in connection with such Accretive Event.



 






    9


     


    

 


		(b)	Within five (5) Business Days after receipt of an Accretive Event Notice by Dr. Malone or on the closing date provided in such Accretive Event Notice and, to the extent practicable, prior to or concurrently with the consummation of the Accretive Event (or, in the case of subsection (ii) of the definition of Accretive Event, prior to the occurrence of the Accretive Event), Dr. Malone or the Trust and the Company shall consummate a Reverse Exchange (the “Reverse Exchange Closing”) at a location and time agreed to by Dr. Malone and the Company; provided, however, that the conditions set forth in Sections 10, 11 and 12 shall have been satisfied (or waived by the party entitled to the benefit thereof).
	 	 	 
	 	(c)	At a Reverse Exchange Closing, on the terms and subject to the conditions contained in this Agreement (including after giving effect to any adjustments in accordance with Section 19(d) hereof):




 


		(i)	Dr. Malone or the Trust shall convey, transfer and deliver to the Company shares of Series B Common Stock of the Group which was the
subject of the Accretive Event in the amount necessary to cause the Malone Voting Power in such Group to be as close as possible to being
equal to, but without being greater than, the Target Voting Power after giving effect to such Accretive Event and Reverse Exchange Closing
(such shares of the applicable Group, the “Reverse Exchange Shares”), free and clear of all Encumbrances other than
Permitted Encumbrances;



 


		(ii)	the Company shall issue and/or deliver to Dr. Malone and the Trust, as applicable, such number of shares of Series C Common Stock
of the same Group as is equal to such number of Reverse Exchange Shares of such Group delivered by Dr. Malone and the Trust, respectively,
and such shares shall be duly authorized, validly issued, fully paid and nonassessable and free and clear of all Encumbrances other than
Permitted Encumbrances; and



 


		(iii)	the Company and Dr. Malone and the Trust, as applicable, will duly execute and deliver a cross receipt each acknowledging the receipt
of the shares of Common Stock delivered to it in connection therewith (the transactions described in this clause (c) being a “Reverse
Exchange”).



 






    10


     


    

 


4.             Exchange Upon Fundamental Events.


 


		(a)	Subject to Sections 4(b) and (c), in the event that the Company proposes to consummate a Fundamental Event in respect
of one or more Groups, then, the Company shall elect (with such election to be at the Company’s sole discretion as approved by a
Special Committee or a majority of the Independent Directors), with respect to each such affected Group, that either



 


		(i)	the Company shall provide for Dr. Malone or the Trust to receive the same per share amount and form of consideration for each Malone
Series C Exchangeable Share of such Group then outstanding and beneficially owned by Dr. Malone or the Trust as the per share amount and
form of consideration to be received by holders of Series B Common Stock of such Group in such Fundamental Event, and Dr. Malone or the
Trust, as applicable, will waive (or cause to be waived) the right to receive the consideration that otherwise would be received with
respect to such Malone Series C Exchangeable Shares of such Group; or



 


		(ii)	immediately prior to the consummation of such Fundamental Event, the Company and Dr. Malone shall consummate, and the Company and
the Trust shall separately consummate, an exchange whereby (x) the Company shall issue and/or deliver to Dr. Malone and/or the Trust,
as applicable, one share of Series B Common Stock of the applicable Group for each Malone Series C Exchangeable Share of the same Group
then outstanding and beneficially owned by Dr. Malone or the Trust, respectively, and (y) Dr. Malone and/or the Trust, as applicable,
shall deliver to the Company their respective Malone Series C Exchangeable Shares of such Group, which shall result in Dr. Malone and
the Trust holding shares of Series B Common Stock of such Group (in lieu of such Malone Series C Exchangeable Shares of such Group) that
are entitled to receive the same per share amount and form of consideration to be received by Dr. Malone and the Trust, respectively,
for his or its other shares of Series B Common Stock of such Group (a “Fundamental Event Exchange” and the consummation
of a Fundamental Event Exchange, a “Fundamental Event Exchange Closing”); provided, however, that the conditions
set forth in Sections 10, 11 and 12 shall have been satisfied (or waived by the party entitled to the benefit thereof).
At a Fundamental Event Exchange Closing, if applicable, the Company and Dr. Malone and the Trust, as applicable, will duly execute and
deliver a cross receipt each acknowledging the receipt of the shares of Common Stock delivered to it in connection therewith.



 


		(b)	If pursuant to the Fundamental Event in respect of a particular Group, the type, form and amount of consideration to be received by
holders of Series B Common Stock and Series C Common Stock of such Group is identical, then Section 4(a) shall be inapplicable
with respect to the Fundamental Event at such Group.



 


		(c)	Notwithstanding the discretion afforded to the Company in Section 4.1(a), if its election of Section 4(a)(i) over Section 4(a)(ii)
(or vice versa) would (x) have a materially more adverse effect from a taxation or regulatory perspective on Dr. Malone or the Trust than
the option not so elected and (y) have no material economic, taxation or regulatory benefit to the Company greater than the option not
so elected, the Company shall not be entitled to make such election without the prior written consent of Dr. Malone.



 






    11


     


    

 


5.             Voting Power Exchange.


 


		(a)	If on (x) the last day of any calendar quarter or (y) a date that is at least five but no more than ten Business Days prior to the
record date for any matter submitted to the stockholders of the Company for a vote, the Malone Voting Power in the Company would be less
than the Target Voting Power if some or all Available Series B Shares of one or more Groups were delivered to Dr. Malone or the Trust
as of such date (the number of Available Series B Shares that may be delivered without resulting in the Malone Voting Power in the Company
exceeding the Target Voting Power, the “Maximum Amount”), Dr. Malone and the Trust may demand (a “Voting Power
Demand”) that the Company exchange the Maximum Amount of Available Series B Shares of any or all Groups on a one for one basis
for shares of Series C Common Stock of such Group or Groups notwithstanding that immediately following such exchange the Malone Voting
Power would exceed the Target Voting Power for any one or more Groups; provided, that (a) following any such exchange, the Malone
Voting Power in the Company must be less than or equal to the Target Voting Power and (b) with respect to any Group where the Malone Voting
Power would exceed the Target Voting Power immediately following such exchange, Dr. Malone and the Trust hereby agree that on any matter
submitted by the Company to the stockholders of that Group, voting together as a separate class, for approval, Dr. Malone and the Trust
will vote, or cause to be voted, the Voting Securities of such Group beneficially owned by them that represent voting power in excess
of the Target Voting Power of such Group in the same manner and in the same proportion as voted by the holders of Voting Securities of
that Group other than Dr. Malone and any holder of Voting Securities beneficially owned by Dr. Malone, and his or their Controlled Affiliates
(the “Other Voting Securities”), such that, for any such matter, the Voting Securities beneficially owned by Dr. Malone
in excess of the Target Voting Power of such Group shall reflect voting results with respect to “shares voted for”, “shares
voted against”, “shares abstained”, “broker non-votes” and “shares not present at the meeting”
proportionate to such aggregate voting results for the Other Voting Securities.
	 	 	 
	 	(b)	No later than four (4) Business Days after the receipt
by the Company of written notice by Dr. Malone or the Trust of a Voting Power Demand (which notice shall specify the number of Voting
Securities beneficially owned by Dr. Malone with respect to each Group and with respect to the Company), Dr. Malone or the Trust and the
Company shall consummate a Voting Power Exchange (the “Voting Power Exchange Closing”) at a location and time agreed
to by Dr. Malone and the Company; provided, however, that the conditions set forth in Sections 10, 11 and 12
shall have been satisfied (or waived by the party entitled to the benefit thereof).



 






    12


     


    

 


 



  


		(c)	At any Voting Power Exchange Closing, on the terms and subject to the conditions contained in this Agreement (including after giving
effect to any adjustments in accordance with Section 19(d) hereof):




 


		(i)	Dr. Malone and the Trust, as applicable, shall convey, transfer and deliver to the Company a number of shares of Series C Common Stock
of one or more Groups in an amount up to the Maximum Amount of Available Series B Shares of such Group or Groups, free and clear of all
Encumbrances other than Permitted Encumbrances;



 


		(ii)	the Company shall issue and/or deliver to Dr. Malone and the Trust, as applicable, such number of shares of Series B Common Stock
of the same Group or Groups as is equal to such number of shares of Series C Common Stock of such Group or Groups delivered by Dr. Malone
and the Trust, respectively, and such shares of Series B Common Stock shall be duly authorized, validly issued, fully paid and nonassessable
and free and clear of all Encumbrances other than Permitted Encumbrances; and



 


		(iii)	the Company and Dr. Malone and the Trust, as applicable, will duly execute and deliver a cross receipt each acknowledging the receipt
of the shares of Common Stock delivered to it in connection therewith (the transactions described in this clause (c) being a “Voting
Power Exchange”).



 


	6.	Rescission. If the applicable Exchange Event is not consummated either prior
                             to or within ten (10) Business Days following an Exchange Closing, or following a Voting Power Exchange
                             Closing in connection with a stockholder meeting, the applicable meeting of stockholders is cancelled,



 


		(a)	the applicable Exchange will be automatically rescinded and treated as if neither the Exchange nor the Exchange Closing had ever occurred
(the “Rescission”);



 


		(b)	each of the Company, Dr. Malone and the Trust hereby waives, and none of the Company, Dr. Malone or the Trust shall have, any rights,
duties or obligations of any kind (other than rights, duties or obligations to effect the Rescission) in respect of the Exchange to receive
or retain, (x) in the case of Dr. Malone and the Trust, (A) following any Dilutive Event Exchange Closing, any shares of Series B Common
Stock issued or delivered in connection therewith; (B) following any Reverse Exchange Closing, any shares of Series C Common Stock issued
or delivered in connection therewith; (C) following any Fundamental Event Exchange Closing, any shares of Series B Common Stock issued
or delivered in connection therewith; and (D) following a Voting Power Exchange Closing, any shares of Series B Common Stock issued or
delivered in connection therewith (such shares referred to in clauses (A), (B), (C) and (D), collectively the “Malone Rescission
Shares”), and, (y) in the case of the Company, (A) following any Dilutive Event Exchange Closing, any shares of Series C Common
Stock delivered in connection therewith; (B) following any Reverse Exchange Closing, any Reverse Exchange Shares delivered in connection
therewith; (C) following any Fundamental Event Exchange Closing, any shares of Series C Common Stock delivered in connection therewith;
and (D) following a Voting Power Exchange Closing, any shares of Series C Common Stock delivered in connection therewith (such shares
referred to in clauses (A), (B), (C) and (D), collectively the “Company Rescission Shares”); and



 






    13 


     


    

 


		(c)	each of the Company, on the one hand, and Dr. Malone and the Trust, on the other hand, will take such actions as are reasonably necessary
to effect such Rescission, and each will be deemed, upon the effectiveness of such Rescission, to make appropriate representations and
warranties to the other with respect to the valid issuance and conveyance, as applicable, and the lack of any Encumbrances upon the Malone
Rescission Shares or the Company Rescission Shares (other than Permitted Encumbrances), as applicable, so as to vest in the other good
and valid title to the Malone Rescission Shares or the Company Rescission Shares, as applicable.



 


	7.	Representations.




 


		(a)	Representations of Dr. Malone. Dr. Malone, on behalf of himself individually and as trustee of the Trust, represents and warrants
to the Company that:




 


	 	(i)	as of the date of this Agreement, Dr. Malone beneficially owns the number of shares of each series and Group of Common Stock set forth
on Exhibit A hereto;




 


	 	(ii)	(w) as of any Dilutive Event Exchange Closing, Dr. Malone will beneficially own or own of record such number of shares of Series C Common
Stock of the applicable Group to be delivered and exchanged by Dr. Malone or the Trust at the Dilutive Event Exchange Closing, free and
clear of all Encumbrances other than Permitted Encumbrances, (x) as of any Reverse Exchange Closing, Dr. Malone will beneficially own
or own of record such number of Reverse Exchange Shares of the applicable Group to be delivered and exchanged by Dr. Malone or the Trust
at the Reverse Exchange Closing, free and clear of all Encumbrances other than Permitted Encumbrances, (y) as of any Fundamental Event
Exchange Closing, Dr. Malone will beneficially own or own of record such number of Malone Series C Exchangeable Shares of the applicable
Group to be delivered and exchanged by Dr. Malone or the Trust at the Fundamental Event Exchange Closing, free and clear of all Encumbrances
other than Permitted Encumbrances, and (z) as of any Voting Power Exchange Closing, Dr. Malone will beneficially own or own of record
such number of shares of Series C Common Stock of the applicable Group or Groups to be delivered and exchanged by Dr. Malone or the Trust
at the Voting Power Exchange Closing, free and clear of all Encumbrances other than Permitted Encumbrances;




 






    14 


     


    

 


	 	(iii)	upon delivery to the Company of the shares of Series C Common Stock, Reverse Exchange Shares or Malone Series C Exchangeable Shares at
the applicable Exchange Closing, in the manner provided in this Agreement, the Company will have good and valid title to such shares
of Series C Common Stock, Reverse Exchange Shares or Malone Series C Exchangeable Shares, free and clear of all Encumbrances other than
Permitted Encumbrances and Encumbrances created by the Company or any of its Controlled Affiliates;




 


	 	(iv)	the Trust is a trust duly organized and validly existing under the Laws of the State of Florida and each of Dr. Malone and the Trust
have all requisite legal capacity to execute and deliver this Agreement and to perform their obligations under this Agreement, including
any Exchange and the other transactions contemplated hereby;




 


	 	(v)	this Agreement has been duly and validly executed and delivered by Dr. Malone and the Trust and, assuming the due execution and delivery
hereof by the Company, is a valid and binding agreement of Dr. Malone and the Trust, enforceable in accordance with its terms, except
as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar Laws affecting creditors’
rights generally, or by principles governing the availability of equitable remedies;




 


	 	(vi)	the execution, delivery and performance by Dr. Malone and the Trust of this Agreement and the consummation by Dr. Malone or the Trust
of any Exchange and the other transactions contemplated hereby requires no action by or in respect of, or filings with, any Governmental
Authority other than (x) as may be required by Competition Laws, including the HSR Act, (y) such clearances, consents, approvals, Orders,
licenses, authorizations, registrations, declarations, permits, filings and notifications as may be required under applicable securities
Laws and (z) any actions or filings under Laws (other than Competition Laws) the absence of which would not reasonably be expected, individually
or in the aggregate, to have a material adverse effect on the ability of Dr. Malone or the Trust to consummate any Exchange or the other
transactions contemplated hereby, or prevent or materially delay the consummation of any Exchange or the other transactions contemplated
by this Agreement;




 






    15 


     


    

 


	 	(vii)	the execution and delivery of this Agreement, and the performance by Dr. Malone and the Trust of this Agreement and the consummation
by Dr. Malone or the Trust of any Exchange and the other transactions contemplated hereby will not (x) violate any applicable Law,
(y) conflict with or constitute a default, breach or violation of (with or without notice or lapse of time, or both) the terms, conditions
or provisions of, or result in the acceleration of (or the creation in any Person of any right to cause the acceleration of) any performance
of any obligation or any increase in any payment required by, or the termination, suspension, modification, impairment or forfeiture
(or the creation in any Person of any right to cause the termination, suspension, modification, impairment or forfeiture) of any contract,
agreement or instrument to which Dr. Malone or the Trust is subject, which would prevent Dr. Malone or the Trust from performing any
of their obligations hereunder, or (z) require any consent by or approval of or notice to any other Person or entity (other than a Governmental
Authority), except, in the case of clauses (x), (y) and (z), as would not have a material adverse effect, individually or in the aggregate,
on Dr. Malone’s or the Trust’s ability to consummate any Exchange or the other transactions contemplated hereby, or prevent
or materially delay the consummation of any Exchange or the other transactions contemplated by this Agreement; and




 


	 	(viii)	each of Dr. Malone and the Trust is a sophisticated investor and an accredited investor (as defined in Rule 501(a) of Regulation D of
the Securities Act), with sufficient knowledge and experience in financial and business matters to evaluate the merits and risks of any
Exchange, and the other transactions contemplated hereby, and each of Dr. Malone and the Trust acknowledges that the offer and sale of
any Company Exchange Shares hereunder has not been registered under the Securities Act or any securities Laws of any state and that such
Company Exchange Shares may not be sold, transferred, offered for sale, pledged, hypothecated or otherwise disposed of without registration
under the Securities Act, except pursuant to an exemption from such registration available under the Securities Act.




 


	 	(b)	Representations of the Company. The Company represents and warrants to Dr. Malone and the Trust that:




 


	 	(i)	upon issuance and/or delivery to Dr. Malone or the Trust of the Company Exchange Shares at an Exchange Closing in the manner provided
in this Agreement, such Company Exchange Shares will be duly authorized, validly issued, fully paid and nonassessable and Dr. Malone
or the Trust, as applicable, will have good and valid title to such Company Exchange Shares so delivered, free and clear of all Encumbrances
other than Permitted Encumbrances and Encumbrances created by Dr. Malone or any of his Affiliates;




 


	 	(ii)	the Company is a Delaware corporation duly organized, validly existing and in good standing under the Laws of the State of Delaware,
and has full power and authority to execute and deliver this Agreement and to consummate any Exchange and the other transactions contemplated
hereby;




 


	 	(iii)	the execution and delivery of this Agreement by the Company, and performance of this Agreement by the Company, including the consummation
of any Exchange and the other transactions contemplated hereby, has been duly authorized by all requisite corporate power;




 






    16 


     


    

 


	 	(iv)	this Agreement has been duly and validly executed and delivered by the Company and, assuming the due execution and delivery hereof by
Dr. Malone and the Trust, is a valid and binding agreement of the Company, enforceable in accordance with its terms, except as such enforceability
may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar Laws affecting creditors’ rights generally,
or by principles governing the availability of equitable remedies;




 


	 	(v)	the execution, delivery and performance by the Company of this Agreement and the consummation by the Company of any Exchange, and the
other transactions contemplated hereby requires no action by or in respect of, or filings with, any Governmental Authority, other than
(x) as may be required by any Competition Laws, including the HSR Act, (y) such clearances, consents, approvals, Orders, licenses, authorizations,
registrations, declarations, permits, filings and notifications as may be required under applicable securities Laws and (z) any actions
or filings under Laws (other than Competition Laws) the absence of which would not reasonably be expected, individually or in the aggregate,
to have a material adverse effect on the ability of the Company to consummate any Exchange or the other transactions contemplated hereby
or prevent or materially delay the consummation of any Exchange or the other transactions contemplated by this Agreement; and




 


	 	(vi)	the execution, delivery and performance by the Company of this Agreement and the consummation of any Exchange and the other transactions
contemplated hereby will not (x) violate any applicable Law, (y) conflict with or constitute a default, breach or violation of (with
or without notice or lapse of time, or both) the terms, conditions or provisions of, or result in the acceleration of (or the creation
in any Person of any right to cause the acceleration of) any performance of any obligation or any increase in any payment required by,
or the termination, suspension, modification, impairment or forfeiture (or the creation in any Person of any right to cause the termination,
suspension, modification, impairment or forfeiture) of any contract, agreement or instrument to which the Company is subject, including
without limitation the Company Charter, the Company Bylaws or similar organization documents of any of the Company’s Controlled
Affiliates, which would prevent it from performing any of its obligations hereunder, or (z) require any consent by or approval of or
notice to any other Person or entity (other than a Governmental Authority), except, in the case of clauses (x), (y) and (z), as would
not have a material adverse effect, individually or in the aggregate, on the Company’s ability to consummate any Exchange and the
other transactions contemplated hereby, or prevent or materially delay the consummation of any Exchange and the other transactions contemplated
by this Agreement.




 






    17 


     


    

 


	8.	Reasonable Best Efforts and Other Covenants.




 


	 	(a)	The Company, Dr. Malone and the Trust shall cooperate with each other and use their reasonable best efforts to (i) consummate any Exchange
and any other transactions contemplated by this Agreement in the manner contemplated by this Agreement and (ii) execute documents reasonably
necessary to effect any Exchange and any other transactions contemplated by this Agreement.




 


	 	(b)	The Company, Dr. Malone and the Trust shall cooperate with each other and shall prepare and file all necessary filings, applications,
notices and/or similar instruments or documentation, and use their respective reasonable best efforts to obtain as promptly as practicable
all consents, approvals or non-objections, as applicable, of all third parties and Governmental Authorities that, in each case, are required
under applicable Law to consummate any Exchange and the other transactions contemplated by this Agreement.




 


	 	(c)	Dr. Malone (directly or through his executors, administrators, or testamentary trustees) may Transfer the right to receive Available
Series B Shares of any one or more Groups to, and only to (i) prior to Dr. Malone’s death or incapacity, a Proposed Transferee
who prior to such Transfer executes a Successor Exchange Agreement covering all shares of Series B Common Stock of such Group then beneficially
owned by Dr. Malone and all Available Series B Shares of such Group or (ii) a Proposed Transferee who, within three months of Dr. Malone’s
death or incapacity, executes a Successor Exchange Agreement covering all shares of Series B Common Stock of such Group beneficially
owned by Dr. Malone immediately prior to his death or incapacity and all Available Series B Shares of such Group; provided, that
any Available Series B Shares hereunder may be released or exchanged to such a Proposed Transferee only following the execution of a
Successor Exchange Agreement on the terms and subject to the conditions of such Successor Exchange Agreement. For the avoidance of doubt,
neither Dr. Malone nor the Trust shall Transfer the right to obtain any Available Series B Shares (including through a series of one
or more Transfers of Series B Common Stock (including Available Series B Shares issued and/or delivered in a Dilutive Event Exchange)
to the same Person or Persons) except to a Proposed Transferee pursuant to a Successor Exchange Agreement, and Available Series B Shares
hereunder may be released or exchanged only on the terms and subject to the conditions of this Agreement or a Successor Exchange Agreement.
The Company shall negotiate in good faith a Successor Exchange Agreement with each Proposed Transferee to whom Dr. Malone (directly or
through his executors, administrators or testamentary trustees) seeks to Transfer Available Series B Shares pursuant to this Section
8(c).




 


	 	(d)	Dr. Malone shall promptly provide notice to the Company of any Transfer or acquisition by Dr. Malone or the Trust of any Voting Securities.




 






    18 


     


    

 


	 	(e)	Unless otherwise determined by a Special Committee or a majority of the Independent Directors, in connection with any Fundamental Event
involving (i) a split-off or spin-off or (ii) a combination, consolidation or merger as a result of which the stockholders of the Company
are entitled to receive all or substantially all of the Voting Securities of the Surviving Company and, in each case, Dr. Malone would
(A) serve as an officer or director of the Surviving Company entitling him to the exemptions provided by Rule 16b-3 promulgated under
the Exchange Act if an Exchange were approved by the board of directors of the Surviving Company or a committee of such board of directors
composed solely of two or more Non-Employee Directors (as defined in such Rule) and (B) beneficially own 40% or more of the outstanding
voting power of the Surviving Company, Dr. Malone, the Trust and the Company (acting through a Special Committee or the Independent Directors)
shall, and shall cause the Surviving Company to, negotiate an exchange agreement with respect to the Surviving Company in substantially
the form of this Agreement in order to replicate the benefits and obligations of Dr. Malone, the
Trust and the Company as exist under this Agreement as of the effective time of such Fundamental Event.




 


	 	(f)	In the event Dr. Malone no longer serves as an officer or director of the Company such that Rule 16b-3 promulgated under the Exchange
Act would not be available to exempt the Exchange transactions hereunder, then neither Dr. Malone nor the Trust shall be required to
participate in any Exchange (including, without limitation any Reverse Exchange) that would result in liability under Section 16(b) of
the Exchange Act.




 


	9.	Tax Matters. Each of the Company, the Trust and Dr. Malone acknowledges and agrees that each Exchange is a transaction intended
to qualify, for U.S. federal income tax purposes, as an exchange pursuant to Section 1036(a) of the Code and/or a reorganization under
Section 368(a)(1)(E) of the Code, in either case, which is tax-free except to the extent of any consideration received by the Trust or
Dr. Malone other than Company Exchange Shares, and except to the extent otherwise required pursuant to a “determination”
(within the meaning of Section 1313(a) of the Code) or a change in applicable Tax Law occurring after the date of this Agreement, the
Company, the Trust and Dr. Malone agree not to take any position on any Tax Return, or take any position for Tax purposes, that is inconsistent
with any Exchange qualifying for U.S. federal income tax purposes as an exchange under Section 1036(a) of the Code and/or a reorganization
under Section 368(a)(1)(E) of the Code which is tax-free except to the extent of any consideration received by the Trust or Dr. Malone
other than Company Exchange Shares; provided, that in the event of a Rescission, the Company, the Trust and Dr. Malone shall not take
any position on any Tax Return, or take any position for Tax purposes, that is inconsistent with an Exchange and any exchange effecting
a Rescission (a “Rescission Exchange”) qualifying, for U.S. federal income tax purposes, either (A) to the extent
the Exchange and a corresponding Rescission Exchange occur in the same tax year, as disregarded transactions or exchanges under Section
1036(a) of the Code which are disregarded or tax-free, as applicable, except to the extent of any consideration received by the Trust
or Dr. Malone other than Company Exchange Shares and Company Rescission Shares, or (B) to the extent the Exchange and the corresponding
Rescission Exchange occur in different tax years, as exchanges under Section 1036(a) of the Code which are tax-free except to the extent
of any consideration received by the Trust or Dr. Malone other than Company Exchange Shares and Company Rescission Shares. For the avoidance
of doubt, consideration received by the Trust or Dr. Malone includes, as applicable, any costs or expenses paid on behalf of or reimbursed
to the Trust or Dr. Malone. This Agreement shall constitute a “plan of reorganization” within the meaning of Sections 1.368-2(g)
and 1.368-3(a) of the U.S. Treasury Regulations promulgated under the Code with respect to each Exchange under this Agreement. At each
Exchange Closing, Dr. Malone and the Trust shall each provide to the Company a valid executed Internal Revenue Service Form W-9 (or applicable
successor form) reasonably satisfactory to the Company with respect to Dr. Malone and the Trust, respectively.




 






    19 


     


    

 


	10.	Conditions to Parties’ Obligation to Effect an Exchange. The respective obligations of the Company, Dr. Malone and the Trust
to effect any Exchange shall be subject to the satisfaction, by each of Dr. Malone, the Trust and the Company prior to or at the relevant
Exchange Closing of the following conditions:




 


	 	(a)	No Injunctions or Restraints. No Order entered, enacted, promulgated, enforced or issued by any court or other Governmental Authority
of competent jurisdiction, shall be in effect which prohibits, renders illegal or enjoins the consummation of such Exchange; and




 


	 	(b)	Occurrence of Event.




 


		(i)	Dilutive Event. In the case of a Dilutive Event Exchange, the relevant Dilutive Event shall have occurred.



 


		(ii)	Accretive Event. In the case of a Reverse Exchange, the relevant Accretive Event shall have already occurred or be reasonably
expected to occur concurrently with or promptly following the Reverse Exchange.



 


		(iii)	Fundamental Event. In the case of a Fundamental Event Exchange, the relevant Fundamental Event shall be reasonably expected
to occur immediately following the Fundamental Event Exchange.



 


	11.	Conditions to the Company’s Obligation to Effect an Exchange. The obligation of the Company to effect any Exchange is also
subject to the satisfaction, or (to the extent legally permissible) waiver in writing by the Company, prior to or at the relevant Exchange
Closing of the following conditions:




 


	 	(a)	Representations and Warranties. The representations and warranties of Dr. Malone and the Trust set forth in Section 7(a)
shall be true and correct in all material respects in each case as of the date of this Agreement and as of the Exchange Closing as though
made on and as of the Exchange Closing, except for (x) those representations and warranties made as of a specified date, which shall
be true and correct in all material respects as of such date, and (y) de minimis inaccuracies;




 






    20 


     


    

 


	 	(b)	Covenants. Dr. Malone and the Trust shall have performed in all material respects all covenants required to be performed by them
prior to or at such Exchange Closing; and




 


	 	(c)	Closing Certificate. Dr. Malone and the Trust shall have delivered to the Company a certificate duly signed by Dr. Malone, individually
and as trustee of the Trust, that the conditions set forth in Sections 11(a) and (b) have been satisfied.




 


	12.	Conditions to Dr. Malone’s and the Trust’s Obligation to Effect an Exchange. The obligation of Dr. Malone and the
Trust to effect any Exchange is also subject to the satisfaction, or (to the extent legally permissible) waiver in writing by Dr. Malone
(individually and as trustee of the Trust), prior to or at the relevant Exchange Closing of the following conditions:




 


	 	(a)	Representations and Warranties. The representations and warranties of the Company set forth in Section 7(b) shall be true
and correct in all material respects in each case as of the date of this Agreement and as of the Exchange Closing as though made on and
as of the Exchange Closing, except for (x) those representations and warranties made as of a specified date, which shall be true and
correct in all material respects as of such date, and (y) de minimis inaccuracies;




 


	 	(b)	Covenants. The Company shall have performed in all material respects all other covenants required to be performed by it prior
to or at such Exchange Closing;




 


	 	(c)	Section 16b-3. The Board or a committee of the Board composed solely of two or more Non-Employee Directors (as defined in Rule
16b-3 promulgated under the Exchange Act) shall have adopted resolutions exempting the Exchange under Rule 16b-3 promulgated under the
Exchange Act; and




 


	 	(d)	Officer’s Certificate. The Company shall have delivered to Dr. Malone and the Trust a certificate duly signed by a duly
authorized officer of the Company that the conditions set forth in Sections 12(a), (b) and (c) have been satisfied.




 


	13.	Termination.




 


		(a)	This Agreement will terminate and no longer apply with respect to the Common Stock of any particular Group beneficially owned by Dr.
Malone (i) upon the mutual consent of each of the parties hereto in a written instrument (in the case of the Company, upon the approval
of a Special Committee or a majority of Independent Directors), (ii) upon execution of a Successor Exchange Agreement covering all shares
of Series B Common Stock of such Group then beneficially owned by Dr. Malone and all Available Series B Shares of such Group or (iii)
other than in a circumstance where this Agreement is terminated pursuant to Section 13(a)(ii), upon the Malone Voting Power ceasing to
constitute at least 20% of the outstanding voting power of such Group.



 






    21 


     


    

 


		(b)	This Agreement will terminate in its entirety and immediately cease to be of any further force and effect (i) pursuant to the mutual
consent of each of the parties hereto in a written instrument (in the case of the Company, upon the approval of a Special Committee or
a majority of Independent Directors), (ii) upon execution of a Successor Exchange Agreement covering all shares of Series B Common Stock
then beneficially owned by Dr. Malone and all Available Series B Shares of all Groups, or (iii) other than in a circumstance where this
Agreement is terminated pursuant to Section 13(b)(ii), upon the Malone Voting Power ceasing to constitute at least 20% of the outstanding
voting power of the Company.



 


		(c)	If this Agreement is terminated in accordance with Section 13(b), this Agreement shall forthwith become null and void and of
no effect and the rights and obligations of the parties hereto shall terminate, without liability of any party (or any stockholder, director,
officer, employee, consultant, financial advisor, legal counsel, financing source, accountant, insurer or other advisor, agent or representative
of such party); provided, that, (i) in the event of a termination as a result of the death of Dr. Malone, the Company’s obligation
in the last sentence of Section 8(c) shall survive for three months following such termination and (ii) nothing contained herein shall
relieve any party to this Agreement from any liability for damages resulting from (x) fraud or (y) willful material breach by such party
prior to such termination, in each case, as determined by a court of competent jurisdiction pursuant to a final and nonappealable judgment.
For purposes of this Agreement, “willful material breach” means a material breach of a party’s covenants and agreements
set forth in this Agreement that is the consequence of an act or omission by a party with the knowledge that the taking of such act or
failure to take such action would be a material breach of such party’s covenants or agreements (provided, that, with respect
to the Company, knowledge includes the actual knowledge, after due inquiry, of the senior executive management team of the Company).



 


		(d)	For the avoidance of doubt, (i) upon the termination of this Agreement with respect to any Group (other than a termination pursuant
to Section 13(a)(ii)), any and all Available Series B Shares of such Group, if any, will be immediately and automatically forfeited and
cancelled and no Person shall have any right to obtain any such Available Series B Shares of such Group and (ii) upon the termination
of this Agreement with respect to the Company (other than a termination pursuant to Section 13(b)(ii), any and all Available Series B
Shares, if any, will be immediately and automatically forfeited and cancelled and no Person shall have any right to obtain any Available
Series B Shares; provided, however, that upon the termination of this Agreement following the death of Dr. Malone, the executors,
administrators or testamentary trustees of Dr. Malone may Transfer the right to receive Available Series B Shares of any one or more Groups
pursuant to, and only pursuant to, Section 8(c) hereof.



 


	14.	Applicable Law. All disputes, claims or controversies arising out of or relating to this Agreement, or the negotiation, validity
or performance of this Agreement, or any Exchange and the other transactions contemplated hereby shall be governed by and construed in
accordance with the Laws of the State of Delaware without regard to its rules of conflict of Laws.




 






    22 


     


    

 


	15.	Jurisdiction. Each of the parties hereto (a) irrevocably and unconditionally consents to submit itself to the sole and exclusive
personal jurisdiction of the Court of Chancery of the State of Delaware, or, solely if that court does not have subject matter jurisdiction,
the Superior Court of the State of Delaware, or, solely if the subject matter of the Action is one over which exclusive jurisdiction
is vested in the courts of the United States of America, a federal court sitting in the State of Delaware (collectively, the “Delaware
Courts”) in connection with any dispute, claim, or controversy arising out of or relating to this Agreement, any Exchange,
or the other transactions contemplated hereby, (b) waives any objection to the laying of venue of any such litigation in any of the Delaware
Courts, (c) agrees not to plead or claim in any such court that such litigation brought therein has been brought in an inconvenient forum
and agrees not otherwise to attempt to deny or defeat such personal jurisdiction or venue by motion or other request for leave from any
such court, and (d) agrees that it will not bring any Action in connection with any dispute, claim, or controversy arising out of or
relating to this Agreement or any Exchange and the other transactions contemplated hereby, in any court or other tribunal, other than
any of the Delaware Courts. All Actions arising out of or relating to this Agreement or any Exchange and the other transactions contemplated
hereby shall be heard and determined in the Delaware Courts. Each of the parties hereto hereby irrevocably and unconditionally agrees
that service of process in connection with any dispute, claim, or controversy arising out of or relating to this Agreement, any Exchange
and the other transactions contemplated hereby may be made upon such party by prepaid certified or registered mail, with a validated
proof of mailing receipt constituting evidence of valid service, directed to such party at the address specified in Section 18
hereof. Service made in such manner, to the fullest extent permitted by applicable Law, shall have the same legal force and effect as
if served upon such party personally within the State of Delaware. Nothing herein shall be deemed to limit or prohibit service of process
by any other manner as may be permitted by applicable Law.




 


	16.	Waiver of Jury Trial.  EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES ALL RIGHT TO TRIAL BY JURY IN ANY ACTION, PROCEEDING
OR COUNTERCLAIM (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO THIS AGREEMENT OR ANY EXCHANGE AND THE OTHER
TRANSACTIONS CONTEMPLATED HEREBY OR THE ACTIONS OF ANY PARTY HERETO IN THE NEGOTIATION, ADMINISTRATION, PERFORMANCE AND ENFORCEMENT OF
THIS AGREEMENT. EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT (A) NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED,
EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER, (B) IT UNDERSTANDS
AND HAS CONSIDERED THE IMPLICATIONS OF SUCH WAIVER, (C) IT MAKES SUCH WAIVER VOLUNTARILY AND (D) IT HAS BEEN INDUCED TO ENTER INTO THIS
AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVER AND CERTIFICATIONS IN THIS SECTION 16.




 






    23 


     


    

 


	17.	Enforcement of this Agreement. The parties acknowledge and agree that irreparable damage would occur and that the parties would
not have any adequate remedy at Law in the event that any of the provisions of this Agreement were not performed in accordance with their
specific terms or were otherwise breached and that monetary damages, even if available, would not be an adequate remedy therefor. It
is accordingly agreed that the parties shall be entitled to an injunction or injunctions to prevent breaches of this Agreement (without
the obligation to post a bond therefor) and to enforce specifically the terms and provisions of this Agreement in the Court of Chancery
of the State of Delaware, this being in addition to any other remedy to which they are entitled at Law or in equity.




 


	18.	Notices. All notices, requests, claims, demands and other communications under this Agreement shall be in writing and shall be
deemed given (a) on the date of delivery if delivered personally or sent via e-mail or (b) on the first (1st) Business Day following
the date of dispatch if sent by a nationally recognized overnight courier (providing proof of delivery), in each case to the parties
at the following addresses (or at such other address for a party as shall be specified by like notice):




 


if to Dr. Malone or the Trust, to:


 


John C. Malone

c/o Liberty Media Corporation

12300 Liberty Boulevard

Englewood, CO 80112

E-Mail: [Separately provided]


 


with a copy (which shall not constitute notice) to:


 


Sherman & Howard L.L.C.

633 Seventeenth Street


Suite 3000


Denver, CO 80202


	 	Attention:	Steven D. Miller




	 	 	Jeffrey R. Kesselman




	 	E-Mail:	[Separately provided]




	 	 	[Separately provided]




 


if to the Company, to:


 


Liberty Media Corporation


12300 Liberty Boulevard


Englewood, CO 80112


Attention: [Separately provided]


Email:[Separately provided]


 






    24 


     


    

 


with a copy (which shall not constitute notice) to:


 


Baker Botts L.L.P.


2001 Ross Avenue


Suite 900


Dallas, Texas 75201


Attention: Samantha Crispin


Email: [Separately provided]


 


	19.	Miscellaneous.




 


	 	(a)	Neither this Agreement nor any of the rights, interests or obligations under this Agreement shall be assigned, in whole or in part, by
operation of Law or otherwise by any of the parties hereto without the prior written consent of the other parties hereto (in the case
of the Company, acting upon the consent of a Special Committee or a majority of the Independent Directors). Any purported assignment
in breach of the foregoing is void ab initio and of no force and effect whatsoever. This Agreement is intended for the benefit
of the parties hereto and is not for the benefit of, nor may any provision hereof be enforced by, any other Person; provided,
however, that Dr. Malone’s executors, administrators and testamentary trustees may, for three months following Dr. Malone’s
death, enforce the last sentence of Section 8(c) hereof.




 


	 	(b)	This Agreement may be executed in separate counterparts, each of which will be an original and all of which taken together will constitute
one and the same agreement.




 


	 	(c)	If, subsequent to the date hereof, further documents are reasonably requested in order to carry out the provisions and purposes of this
Agreement, the parties hereto will execute and deliver such further documents.




 


	 	(d)	When a reference is made in this Agreement to a Section, such reference shall be to a Section of this Agreement unless otherwise indicated.
The headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation
of this Agreement. Whenever the words “include”, “includes” or “including” are used in this Agreement,
they shall be deemed to be followed by the words “without limitation”. The words “hereof”, “herein”
and “hereunder” and words of similar import when used in this Agreement shall refer to this Agreement as a whole and not
to any particular provision of this Agreement. Definitions contained in this Agreement are applicable to the singular as well as the
plural forms of such terms. When this Agreement contemplates a certain number of securities, as of a particular date, such number of
securities (including Available Series B Shares) shall be deemed to be appropriately adjusted (without duplication) to account for stock
splits, stock dividends, recapitalizations, combinations of shares or other change affecting the outstanding shares of the Common Stock
or Voting Securities other than any Fundamental Event subject to Section 4. In the event the Company’s stockholders approve an
amendment to the Company Charter to change the name of a tracking stock group, references to the prior name of such tracking stock group
and its securities in this Agreement shall be deemed to refer to the renamed tracking stock group and its securities.




 






    25 


     


    

 


	 	(e)	Any provision of this Agreement may be amended or waived if, and only if, such amendment or waiver is in writing and signed (i) in the
case of an amendment, by each of parties hereto (in the case of the Company, upon the approval of a Special Committee or a majority of
the Independent Directors), and (ii) in the case of a waiver, by the party against whom the waiver is to be effective (in the case of
the Company, upon the approval of a Special Committee or a majority of the Independent Directors). No failure or delay by any party in
exercising any right, power or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise thereof
preclude any other or further exercise thereof or the exercise of any other right, power or privilege.




 


	 	(f)	If any term or other provision of this Agreement is invalid, illegal or incapable of being enforced by any rule of Law or public policy,
all other conditions and provisions of this Agreement shall nevertheless remain in full force and effect, insofar as the foregoing can
be accomplished without materially affecting the benefits anticipated by the parties to this Agreement. Upon such determination that
any term or other provision is invalid, illegal or incapable of being enforced, the parties hereto shall negotiate in good faith to modify
this Agreement so as to effect the original intent of the parties as closely as possible to the fullest extent permitted by applicable
Law in an acceptable manner to the end that the Exchanges and the other transactions contemplated hereby are fulfilled to the greatest
extent possible.




 


	 	(g)	The parties acknowledge and confirm that each of their respective attorneys have participated jointly in the drafting, review and revision
of this Agreement and that it has not been written solely by counsel for one party and that each party has had the benefit of its independent
legal counsel’s advice with respect to the terms and provisions hereof and its rights and obligations hereunder. Each party hereto,
therefore, stipulates and agrees that the rule of construction to the effect that any ambiguities are to be or may be resolved against
the drafting party shall not be employed in the interpretation of this Agreement to favor any party against another and that no party
shall have the benefit of any legal presumption or the detriment of any burden of proof by reason of any ambiguity or uncertain meaning
contained in this Agreement.




 


	 	(h)	All costs and expenses incurred or to be incurred with this Agreement and the transactions contemplated hereby will be paid by the party
incurring such cost or expense, provided, that the Company shall pay (or reimburse Dr. Malone and the Trust) all reasonable out-of-pocket
costs and expenses incurred by Dr. Malone and the Trust, including the reasonable fees, charges and disbursements of counsel for Dr.
Malone and the Trust and any filing fees due for any filings pursuant to any Competition Law, including the HSR Act, in each case, necessary
or in connection with the preparation, negotiation, execution and consummation of this Agreement and any of the transactions contemplated
by this Agreement.




 


[Signature Page Follows]








 






    26 


     


    

 


IN WITNESS WHEREOF, the parties hereto have executed
this Agreement as of the date first above written.


 


	 	JOHN C. MALONE
	 	/s/ John C. Malone
	 	 
	 	JOHN C. MALONE 1995 REVOCABLE TRUST U/A DTD 3/6/1995
	 	By:	   /s/ John C. Malone
	 	Name:	   John C. Malone
	 	Title:	   Trustee




 






     


     


    

 





	 	LIBERTY MEDIA CORPORATION
	 	By:	   /s/ Renee L. Wilm
	 	Name:	   Renee L. Wilm
	 	Title:	   Chief Legal Officer